GlassScriptPhysician profile
Binaca Gaglani
NPI 1831194240
$1,901.46
in general payments reported to CMS, 2019-2025
14 companies · $628 in 2025
The $628 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $38.11 · 2021: $126 · 2022: $145 · 2023: $408 · 2024: $154 · 2025: $628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,064 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,063.98 |
| Education | $125.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $322.02 | 2019-2025 | Arexvy, Nucala |
| Genzyme Corporation | $315.22 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $141.20 | 2025 | Dupixent |
| Sanofi-Aventis U.S. LLC | $139.97 | 2021-2025 | |
| Genentech USA, INC. | $137.61 | 2025 | Xolair |
| Galderma Laboratories, L.P. | $136.40 | 2025 | Nemluvio |
| Blueprint Medicines Corporation | $126.25 | 2025 | Ayvakit |
| Abbvie INC. | $125.54 | 2022 | |
| Optinose US, INC. | $122.29 | 2023 | |
| Alk-Abello, INC | $115.56 | 2019 | |
| Gilead Sciences, INC. | $94.36 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $58.60 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $52.17 | 2020-2023 | Fasenra |
| Ars Pharmaceuticals Operations, INC. | $14.27 | 2025 | Neffy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Binaca Gaglani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.